Recent Updates
Recently added Catalysts

EOS884448

Phase 1

Advanced Cancer | Small molecule | Oncology |iTeos Therapeutics, Inc.|Last Updated: Sep 19, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment40
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04335253First-In-Human Study of EOS884448 in Participants with Advanced Cancers.PHASE1 COMPLETED 40 — — Feb 18, 2020Apr 7, 2022Sep 19, 20244 Belgium
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentage of participants with Adverse Events
From first dose date to 90 days after the last dose (up to 48 weeks)
Percentage of participants who experience a Dose Limiting Toxicity
From first study treatment administration through Day 28
Define the recommended Phase 2 dose (RP2D) of EOS884448 in participants with advanced tumors.
up to 48 weeks
Secondary Endpoints
Mean and median Area under the curve (AUC) of EOS884448 at each dose level
up to 48 weeks
Mean and median Maximum concentration (Cmax) of EOS884448 at each dose level
up to 48 weeks
Percentage of participants with Objective Response as determined by Investigator according to RECIST v1.1or per other specific response criteria according to their tumor type.
From study enrollment until participant discontinuation, first occurrence of progressive disease, or death from any cause, whichever occurs first (approximately 48 weeks)
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Multiple Ascending DoseEXPERIMENTALDose escalation according to cohort allocation
Interventions
NameTypeDescription
EOS884448DRUGMultiple Ascending Dose
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites4

Inclusion Criteria: 1. Be willing to provide a signed written informed consent for the trial and consent for biopsies before and during administration of EOS884448 2. Be more than18 years of age on day of signing informed consent. 3. Have histologically or cytologically confirmed advanced or metast...

Countries:Belgium
Unlock Eligibility Criteria
Competitive Landscape -Cancer 5 trials
CompanyTickerTrialsLead PhaseDrugs
GE Healthcare Technologies Inc.GEHC1PHASE1GEH200520 / GEH200521 - Part A
Zimmer Biomet Holdings, Inc.ZBH1 — Undisclosed
Ascentage Pharma Group International Unsponsored ADRAAPG1PHASE1Olverembatinib
Unlock Competitive Intelligence